GYN: Endometrial/Uterine Cancer Clinical Trials

Showing 1-4 of 4 items
  • Image-Guided Gynecologic Brachytherapy
  • Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
  • Diagnoses: GYN: Cervical Cancer, GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
  • VB-111+Paclitaxel for Recurrent Mullerian Cancer
  • This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved VB-111, or the combination of VB-111 with paclitaxel for use in patients, including people with your type of cancer. VB-111 is designed to kill cancer cells in the body by "cutting off" the blood flow to cancer cells and/or tumors. The process of "cutting off" the blood flow to cancer cells and/or tumors is known as anti-angiogenesis and has been shown to help prevent tumor growth. VB-111 is both a vascular disrupting (blocking blood vessels) and anti-angiogenic (preventing new blood vessel growth) agent. It is different to normal chemotherapy as it is made from an adenovirus (Cold virus) carrying a human gene that kills cell lining blood vessels (Endothelial cells). This virus is a 'non-replicating' virus, meaning it cannot grow in the body. Paclitaxel is a chemotherapy drug which is FDA approved for use in your type of cancer. In this research study, we are looking for the highest dose of VB-111 that can be given safely in combination with paclitaxel to patients with platinum-resistant ovarian cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
Showing 1-4 of 4 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms